Patent US2340061A successfully refreshed from Google Patents.
US4880429A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prosthetic meniscus
Assignee: Regen Corp
•
Filing: 1987-07-20
•
Granted: 1989-11-14
•
Expires: 2007-07-20
Abstract
Abstract A prosthetic meniscus is disclosed which can be implanted in a humanoid knee, and which can act as a scaffold for regrowth of native meniscal tissues. The meniscus comprises a three dimensional array of collagen fibers interspersed with glycosaminoglycan molecules. The collagen fibers are present at a concentration of about 65 to 98 percent by dry weight, and the glycosaminoglycan molecules are present at a concentration of about 1 to 25 percent by dry weight. Crosslinks are provided by at least a portion of the glycosaminoglycan molecules, and may consist of at least one of the group comprising chondroitan 4-sulfate, chondroitan 6-sulfate, keritan sulfate, dermatan sulfate, heparin sulfate, and hyaluronic acid.
Inventors
- 👤 Kevin R. Stone
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 02:19
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/58; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2/30; A61F2/38; A61F2/3872; A61L27/14; A61L27/20; A61L27/22; A61L27/227; A61L27/24; A61L27/26; A61L27/40; A61L27/44; A61L27/46; A61L27/48; A61F2/30756; A61F2/3094; A61F2/30965; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30108; A61F2002/3011; A61F2002/30112; A61F2002/30131; A61F2002/30199; A61F2002/30205; A61F2002/30667; A61F2002/30677; A61F2/30721; A61F2/30734; A61F2002/30736; A61F2/30767; A61F2/30771; A61F2002/3082; A61F2002/30878; A61F2002/30879; A61F2002/30904; A61F2/42; A61F2/4261; A61F2002/4271; A61F2002/4274; A61F2002/4276; A61F2002/4279; A61F2002/4282; A61F2002/4284; A61F2002/4287; A61F2002/4289; A61F2002/4292; A61F2002/4294; A61F2002/4297; A61F2210/00; A61F2210/0004; A61F2230/00; A61F2230/0002; A61F2230/0004; A61F2230/0013; A61F2230/0063; A61F2230/0067; A61F2310/00; A61F2310/00005; A61F2310/00365; A61L2430/00; A61L2430/06; Y; Y10; Y10S; Y10S128/00; Y10S128/08
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
141 words
A prosthetic meniscus comprising a porous dry volume matrix of Type I collagen fibers interspersed with glycosaminoglycan molecules, wherein said matrix has a substantially wedge shape including a wide central region between two narrow distal tip regions, wherein said collagen fibers are present at a concentration of about 65%-98% by dry weight, wherein said glycosaminoglycan molecules are present at a concentration of about 1%-25% by dry weight, and wherein at least a portion of said molecules provide glycosaminoglycan crosslinks between said collagen fibers, said crosslinks being dispersed substantially nonuniformly throughout said matrix, and said crosslinks having relatively high density at said tip regions and relatively low density at said central region, and wherein said matrix has a pore size substantially in the range 10-50 microns, whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of meniscal fibrochondrocytes.
Claim 2
Dependent Claim
141 words
A prosthetic meniscus comprising a porous dry volume matrix of Type I collagen fibers interspersed with glycosaminoglycan molecules, wherein said matrix has a substantially wedge shape including a wide central region between two narrow distal tip regions, wherein said collagen fibers are present at a concentration of about 65%-98% by dry weight, wherein said glycosaminoglycan molecules are present at a concentration of about 1%-25% by dry weight, and wherein at least a portion of said molecules provide glycosaminoglycan crosslinks between said collagen fibers, said crosslinks being dispersed substantially nonuniformly throughout said matrix, and said crosslinks having relatively high density at said tip regions and relatively low density at said central region, and wherein said matrix has a pore size substantially in the range 10-50 microns, whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of meniscal fibrochondrocytes.
Claim 3
Dependent Claim
29 words
The prosthetic meniscus of claim 1, wherein said glycosaminoglycan molecules consist of at least one of the group comprising:chondroitin 4-sulfate; chondroitin 6-sulfate; keratin sulfate; dermatan sulfate; and hyaluronic acid.
Claim 4
Dependent Claim
19 words
The prosthetic meniscus of claim 2, wherein the dispersion of said glycosaminoglycan molecules is substantially uniform throughout said matrix.
Claim 5
Dependent Claim
19 words
The prosthetic meniscus of claim 2, wherein the dispersion of said glycosaminoglycan molecules is substantially non-uniform throughout said matrix.
Claim 6
Dependent Claim
48 words
The prosthetic meniscus of claim 1, wherein said crosslinks consists of at least one of the group of glycosaminoglycan molecules comprising: chondroitin 4-sulfate; chondroitin 6-sulfate; keratin sulfate; dermatan sulfate; and hyaluronic acid, and wherein the molecular weight of said molecular crosslinks is within the range of 800-60,000 daltons.
Claim 7
Dependent Claim
19 words
The prosthetic meniscus of claim 5 wherein the density of said collagen fibers is substantially uniform throughout said matrix.
Claim 8
Dependent Claim
19 words
The prosthetic meniscus of claim 1, wherein the orientation of said collagen fibers is substantially random throughout said meniscus.
Claim 9
Dependent Claim
19 words
The prosthetic meniscus of claim 1, wherein the density of said collagen fibers is substantially non-uniform throughout said array.
Claim 10
Dependent Claim
26 words
The prosthetic meniscus of claim 1, further comprising a mesh extending from portions of the outer surface of said matrix, said mesh being dissolvable and nonimmunogenic.
Claim 11
Dependent Claim
49 words
The prosthetic meniscus of claim 1, wherein said glycosaminoglycan crosslinks comprises at least one of the group of glycosaminoglycan molecules consisting of:chondroitin 4-sulfate; chondroitin 6-sulfate; keratin sulfate; dermatan sulfate; and hyaluronic acid, and wherein the molecular weight of said molecular crosslinks is within the range of about 800-60,000 daltons.
Claim 12
Dependent Claim
37 words
The prosthetic meniscus of claim 10, wherein said glycosaminoglycan crosslinks are present at a density less than about 0.95 and greater than about 0.50 crosslink/collagen ratio, thereby permitting ingrowth of, and providing support for regenerated meniscal tissue.
Claim 13
Dependent Claim
26 words
The prosthetic meniscus of claim 10, further comprising a mesh extending from portions of the outer surface of said array, said mesh being absorbable and nonimmunogenic.
References Cited (Backward Citations)
US3443261A
Cited
US3551560A
Cited
US3855638A
Cited
US4085466A
Cited
US4280954A
Cited
US4060081A
Cited
GB1515963A
Cited
US4055862A
Cited
US4291013A
Cited
US4351069A
Cited
US4385404A
Cited
CA1170001A
Cited
US4378224A
Cited
US4344193A
Cited
US4400833A
Cited
US4350629A
Cited
US4502161A
Cited
US4472840A
Cited
US4502161B1
Cited
US4418691A
Cited
US4458678A
Cited
US4505266A
Cited
US4542539A
Cited
WO1983003536A1
Cited
US4544516A
Cited
US4448718A
Cited
US4614794A
Cited
US4627853A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-13 | 1993-05-15 | 1993-11-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-13 | 1997-05-15 | 1997-11-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-13 | 2001-05-15 | 2001-11-14 | $7700.00 | Window Closed / Lapsed |